by Chrissy Buteas, President and Chief Executive Officer
HealthCare Institute of New Jersey (HINJ)
March 4, 2026 ― When a patient learns of a life-altering diagnosis – an aggressive blood cancer, a progressive autoimmune disorder, or a rare disease – the first question they’ll ask is: Is there a new treatment that can help me? Increasingly, the answer is yes, thanks to America’s life sciences and the decades of scientific discovery made possible by our unrivaled innovation ecosystem.
But today, a federal “Most Favored Nation” (MFN) drug pricing policy threatens the very system that delivers those life-saving breakthroughs. Worse, it risks ceding America’s global leadership in medical innovation to China – a nation already pouring billions into biopharmaceutical research, tightening its grip on raw materials, and signaling a willingness to weaponize supply chains.
MFN isn’t just a pricing policy. It’s a strategic mistake. Read the full op-ed here.